Nanotherapeutics Advances Two Clinical Programs
Published: Mar 11, 2009
ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced that it has it has submitted an Investigational New Drug (IND) application to the FDA for a Phase I clinical studies to assess the safety and pharmacokinetics of NanoBUP™ buprenorphine / naloxone capsule for the treatment of opiate addiction. NanoBUP™ is a stable, oral swallowed capsule containing buprenorphine / naloxone developed with the company’s proprietary NanoDRY® particle delivery system. This new product is an immediate release capsule that allows buprenorphine to be absorbed more efficiently from the upper gastrointestinal tract upon ingestion, offering a less invasive route of administration and potentially reducing patient-to-patient variability.